News

Video

Novel Therapies for Advanced RCC: LITESPARK-005 and Treatment Sequencing

Author(s):

Ulka Vaishampayan, MD,Alan Tan, MD

Leading oncologists discuss advanced treatment options for patients with progressing renal cell carcinoma (RCC), focusing on the promising results from LITESPARK-005 and treatment sequencing strategies.

Related Videos
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Chad Tang, MD
Related Content
Anita Scheuber, MD, PhD
October 29th 2024

Novel HPK1 Inhibitor NDI-101150 Shows Early Activity in RCC

Guillermo Garcia-Manero, MD, professor, chief, section of Myelodysplastic Syndromes, deputy chair, Translational Research, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
August 19th 2024

Garcia-Manero on MDS Treatment Updates With Luspatercept and Beyond

Wenxin “Vincent” Xu, MD
October 25th 2024

Immunotherapy Combinations Dominate Frontline Discussions in Advanced RCC

Shannon N. Westin, MD, MPH, FACOG, professor, clinical medical director, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center
August 15th 2024

FDA Approval Insights: Durvalumab/Chemotherapy in dMMR Advanced Endometrial Cancer

Alan Tan, MD
October 18th 2024

Long-Term IO-IO Data Contest the Role of Frontline TKIs in Advanced RCC

Neeraj Agarwal, MD, FASCO
October 17th 2024

Cabozantinib Plus Atezolizumab Fails to Improve OS Over Subsequent Novel Hormonal Therapy in mCRPC